Financial Results

News & Events

Inventiva selected to present the positive results from its
Phase IIa clinical study with odiparcil in MPS VI at the 16th
« Annual WORLDSymposiumTM »

February 3, 2020

Daix (France), February 3, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company
developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage
disorders and oncology, today announced that Dr. Nathalie Guffon (MD, Hôpital Femme-Mère-Enfant, Lyon,
France), investigator of the iMProveS (improve MPS treatment) Phase IIa clinical study, will present a poster,
entitled “Treatment of mucopolysaccharidosis type VI patients with odiparcil alone or in addition to enzyme
replacement therapy: A Phase IIa study”, at the 16th Annual WORLDSymposium™ taking place from February 10
to 13, 2020 at the Hyatt Regency Orlando, Orlando, Florida.
Dr. Nathalie Guffon will present the positive results of the iMProveS Phase IIa clinical study published on
December 18, 2019, which showed that odiparcil improved key clinical parameters in several patients such as
corneal clouding and cardiac and respiratory functions. In addition, the clinical study met its safety primary
objective further supporting the good overall safety profile of odiparcil already observed in previous Phase I and
Phase II clinical studies. Based on the iMProveS clinical study results, Inventiva has decided to continue the clinical
development of odiparcil for the treatment of MPS VI.
Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva,said: “We are very excited by the results of the
iMProveS study showing that odiparcil is able to treat hard-to-reach tissues and improve cardiac and respiratory
functions. Given that enzyme replacement therapy as current standard of care shows limited efficacy in these
organs, we believe that odiparcil could become a reference treatment for MPS VI. We look forward to present our
promising results at the upcoming congress and to pursue the clinical development of odiparcil.”


Frédéric Cren

Chief Executive Officer
+33 3 80 44 75 00


Aude Hillion/ Yannick Tetzlaff
Media relations
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.